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Abstract: The prevalence of heart failure is ever increasing around the world, particularly due 
to aging populations. Despite improvements in treatment over the last 20 years, the prognosis 
for heart failure remains poor. Among the treatments recommended for chronic heart failure, 
angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are crucial, provided of 
course that they are not contraindicated. However, angiotensin II receptor blockers (ARBs) 
can also be a beneﬁ  cial treatment option. Candesartan is a particular ARB, characterized by a 
strong binding afﬁ  nity to the angiotensin II type 1 receptor and slow dissociation. The beneﬁ  ts 
of candesartan have been demonstrated by the CHARM programme, which showed that 
candesartan signiﬁ  cantly reduces the incidence of cardiovascular death, hospital admissions 
for decompensated heart failure, and all-cause mortality in chronic heart failure patients with 
altered left ventricular systolic function, when added to standard therapies or as an alternative 
to ACE inhibitors when these are poorly tolerated. Furthermore, candesartan can protect against 
myocardial infarction, atrial ﬁ  brillation and diabetes. Tolerance to candesartan is good, but blood 
pressure and serum potassium and creatinine levels must be monitored.
Keywords: chronic heart failure, angiotensin II receptor blockers, candesartan, left ventricular 
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Introduction
Heart failure (HF) is a major public health issue. Indeed, it is increasingly prevalent 
around the world, particularly among men, in an ageing global population.1,2 Despite 
marked improvements in treatment over the last few decades, prognosis remains poor 
with signiﬁ  cant morbidity (functional impairment, successive hospitalizations) and high 
mortality rates.3 The deaths occur not only at the acute stage, such as after cardiogenic 
shock following a myocardial infarction (MI), but also during the chronic stage.
Once HF is diagnosed, its characteristics need to be speciﬁ  ed: is it left, right or 
both HF? Acute or chronic HF? HF with decreased or preserved left ventricular (LV) 
systolic function? The latter condition is deﬁ  ned by the existence of both HF and an 
LV ejection fraction (LVEF) of 50%.4 It is important to point out at this stage that 
most clinical trials have been carried out on HF patients with LV systolic dysfunction. 
The etiology of HF must consistently be investigated, as treatment partly depends on 
the disease causing it. HF has many causes, the most frequent being ischemic heart 
disease and hypertension.5,6 When HF occurs in a patient, the triggering factors must 
be identiﬁ  ed. These can include myocardial ischemia, infection, rhythm disturbances 
such as atrial ﬁ  brillation (AF) and conduction disturbances, blood pressure rises, poor 
treatment compliance and lifestyle and dietary habits.
Chronic heart failure
Chronic HF is deﬁ  ned as chronic inadequate performance of the heart. In fact, the 
progressive nature of HF can be explained by a complex combination of structural, Vascular Health and Risk Management 2009:5 258
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functional, and biological changes to the heart. In the 2008 
guidelines of the European Society of Cardiology for the 
diagnosis and treatment of acute and chronic HF, HF is 
deﬁ  ned as: “clinical syndrome in which patients have the 
following features: symptoms typical of HF, signs typical 
of HF, and objective evidence of a structural or functional 
abnormality of the heart at rest.”6 HF is therefore diagnosed 
through a medical interview, a clinical examination and 
some other complementary tests (ECG, chest X-ray, B-type 
natriuretic peptide [BNP] and echocardiography).
Treating chronic heart failure
Drug treatment
The best treatment for HF is primary prevention. However, 
despite considerable improvements in the treatment of 
cardiovascular risk factors, HF incidence is increasing. 
Primarily, treatment involves drugs as well as making 
and strictly following certain lifestyle and dietary changes 
(ﬂ  uid restriction, weight monitoring, nutrition and exercise 
training).
At the acute stage, treatment consists of loop diuretics for 
ﬂ  uid retention, inotropic agents for hypotension, oxygen therapy, 
non-invasive ventilation, antiarrhythmics, (amiodarone) 
for supraventricular or ventricular rhythm disturbances, 
antihypertensives (nitrites) for severe hypertension, antibiotics 
for infections and even accelerating the heart rate for excessive 
bradycardia. There are yet more devices and treatments 
available, but describing these is not the objective of this 
review. Of course, at the acute stage, it is imperative to treat the 
triggering factor (eg, coronary angioplasty, treating pneumonia 
or giving a transfusion for severe anemia).
During the chronic stage, HF can be treated with several 
categories of drugs, some of which have been assessed in 
large clinical trials, and others which have long been used 
empirically such as loop diuretics (for symptoms or signs of 
pulmonary or systemic venous congestion) and digoxin (for 
AF or symptomatic HF associated with an LVEF  40%).6 
Four main therapeutic categories are currently used in 
chronic HF treatment: beta-blockers, angiotensin-converting 
enzyme (ACE) inhibitors, aldosterone antagonists and 
angiotensin II type 1 receptor blockers (ARBs). We will 
not discuss mechanical treatments for HF such as cardiac 
resynchronization therapy (biventricular pacing), ventricular 
assist device, artiﬁ  cial heart and heart transplantation.
Beta-blockers
After having initially been contraindicated in cases of HF, 
they are now among the essential drugs for the medical 
treatment of chronic HF. Indeed, not only do they improve 
symptoms but they reduce the frequency of HF recurrence 
and lower the mortality rate connected to this disease.7,8,9 
For this indication, the approved beta-blockers are 
carvedilol, bisoprolol, metoprolol and nebivolol. Dosage 
must be gradually increased until the evidence-based target 
dose is reached or maximal tolerated dose.
ACE inhibitors
The efﬁ  cacy of ACE inhibitors on the symptoms of HF, 
on tolerance of exercise and quality of life, as well as 
upon cardiovascular morbidity and mortality has been 
demonstrated.10,11,12 This beneﬁ  cial action is particularly 
noticeable in cases of reduced LVEF, which can be partially 
reversed with this treatment (it acts upon LV remodeling). 
Therefore, according to the latest European recommendations 
on the treatment of chronic HF, an ACE inhibitor should be 
used, unless contraindicated or not tolerated, in all patients 
with symptomatic HF and an LVEF  40%.6
Aldosterone antagonists
Several studies have shown the beneﬁ  cial role of certain 
aldosterone antagonists in chronic HF patients. Spironolactone 
(for all causes of HF) and eplerenone (for HF after MI) can 
therefore be used in addition to standard therapy in cases of 
LV systolic dysfunction (LVEF  35%–40%), to reduce 
cardiovascular morbidity and mortality linked to HF as well 
as sudden death.13,14 The latest ESC recommendations suggest 
adding a low-dose aldosterone antagonist to the treatment of 
HF patients with an LVEF  35% and severe symptomatic 
HF, in the absence of hyperkalemia and signiﬁ  cant renal 
dysfunction.6
Angiotensin receptor blockers
ARBs are an effective treatment against the harmful effects 
of the activation of the renin-angiotensin-aldosterone system 
(RAAS), which occur during hypertension or diabetes for 
example.15,16,17,18 The RAAS is also involved in the physio-
pathology of HF, and for this reason, the effect of ARBs has 
been studied in chronic HF sufferers.
The ﬁ  rst clinical trial involving ARBs in the treatment 
of chronic HF was the ELITE study (Evaluation of Losar-
tan In The Elderly), published in 1997, on a population of 
722 patients aged over 65 suffering from HF with LV systolic 
dysfunction (LVEF  40%).19 Its objective was to determine 
whether losartan offers safety and efﬁ  cacy advantages in the 
treatment of HF over ACE inhibition with captopril. In this 
study, losartan was generally better tolerated than captopril. 
Moreover, treatment with losartan was associated with an Vascular Health and Risk Management 2009:5 259
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unexpected lower mortality rate than that found with captopril. 
In order to conﬁ  rm losartan’s advantage over captopril in terms 
of increased survival rates and tolerance, the investigators of 
the ELITE study then carried out the ELITE II study among 
3152 patients aged over 60 with NYHA class II–IV HF and 
LVEF  40%.20 There were no signiﬁ  cant differences in 
all-cause mortality or sudden death or resuscitated arrests 
between the two treatment groups. These results are all the 
more so disappointing since the ELITE II study raised the 
possibility of a negative outcome in chronic HF patients when 
losartan is combined with a beta-blocker.
The Val-HeFT trial (Valsartan Heart Failure Trial) 
was carried out among 5010 subjects with LV systolic 
dysfunction (LVEF  40%).21 Its objective was to evaluate 
the long-term effects of the addition of valsartan to standard 
therapy (including an ACE inhibitor in 93% of patients 
and a beta-blocker in 35%) for HF. Although mortality 
rates were identical with both valsartan and the placebo, 
the combined endpoint (cardiovascular morbidity and 
mortality) was signiﬁ  cantly reduced (–13%, p = 0.009) in 
the valsartan group, predominantly because fewer patients 
were hospitalized for HF (a 24% reduction in HF hospital 
admissions). It must be mentioned that this study revealed an 
increase in cardiovascular morbidity and mortality in patients 
who received the triple combination of an ACE inhibitor, 
a beta-blocker and valsartan. Following the release of this 
information, international recommendations on the treatment 
of HF discouraged RAAS blockade using this triple therapy 
approach. These guidelines were then modiﬁ  ed following the 
release of the results of the CHARM programme.6
Several studies have shown the beneﬁ  cial action of ACE 
inhibitors after an MI, particularly in cases of HF with LV 
systolic dysfunction.22,23,24 The advantage of ARBs in these 
conditions, either alone or in conjunction with an ACE 
inhibitor, was analyzed in the VALIANT study (Valsartan 
in Acute Myocardial Infarction).25 This study involved 
14,703 patients who had recently presented an MI and 
who had presented signs of HF (either clinical or on X-ray 
examination) or an LVEF  35%–40%, or both. After a 
25-month follow-up period, the conclusions showed valsartan 
to be as effective as captopril within this population but that 
combining valsartan with captopril increased the rate of 
adverse events without improving survival.
Generally speaking, almost half of HF patients have an 
LVEF of at least 45%. Patients are typically elderly and 
hypertensive. There is no established management strategy in 
such cases and it is logical to consider using RAAS blockers, 
ARBs in particular. The ﬁ  rst large study to have provided 
some indications in this context is the CHARM-Preserved 
study which will be discussed later in this review.26 The 
I-Preserve study (Irbesartan in heart failure with Preserved 
ejection fraction) has just been published.27 This is a study 
involving 4128 subjects aged 60+ with NYHA class II, III or 
IV and an LVEF  45%. After a 49-month follow-up period, 
during which the patients received irbesartan (300 mg) or a 
placebo as well as the standard therapy (45% received an 
ACE inhibitor during the study), all-cause mortality rates and 
hospitalization rates for cardiovascular causes were identical 
in the two treatment groups (36% versus 37%).
Candesartan in chronic HF
Candesartan cilexetil is an ARB that is characterized by 
the strongest binding afﬁ  nity to the angiotensin II type 1 
receptor and its slow dissociation.28 It was ﬁ  rst used in the 
treatment of hypertension. In this indication, the molecule is 
particularly well tolerated.29 Candesartan has subsequently 
been used in chronic HF. Experimental studies have shown 
that, in rats, long-term angiotensin II type 1 receptor block-
ade by candesartan prevented the development of diastolic 
HF through attenuation of LV relaxation abnormality and 
myocardial stiffening.30
HF with LV systolic dysfunction
The RESOLVD study (Randomized Evaluation of Strate-
gies for Left Ventricular Dysfunction) This study dem-
onstrated that a combination of candesartan (4 or 8 mg) 
and ramipril (20 mg) had a positive effet on hemodynamic 
parameters, LV remodeling and neurohormonal activ-
ity in 768 patients with an LVEF  40% and a 6-minute 
walk distance  500 meters.31 A post-hoc analysis of this 
study revealed that the patients who beneﬁ  ted the most from 
the candesartan plus ramipril combination were those who 
also received a beta-blocker (metoprolol).32
The CHARM-Added trial
The CHARM (Candesartan in Heart failure: Assessment of 
Reduction in Mortality and morbidity) was a programme 
of clinical trials designed to address a large spectrum of 
symptomatic HF patients (Figure 1). It involved three distinct 
trials running in parallel: randomized double-blind comparisons 
of candesartan to placebo. Each trial in the CHARM programme 
was independently designed to determine whether the addition 
of candesartan (from 4 to 8 mg daily to 32 mg daily) to other 
HF therapies would reduce the risk of cardiovascular death or 
hospital admissions for chronic HF. The CHARM programme 
included a total of 7601 patients with chronic HF overall.Vascular Health and Risk Management 2009:5 260
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We know that RAAS plays a major role during chronic 
HF. It therefore seems justiﬁ  able to attempt to block this 
neurohormonal system as effectively as possible in order to 
optimise the treatment of this disease. This blocking action 
can be achieved with an ACE inhibitor, an ARB or even a 
combination of the two. With this in mind, the CHARM-
Added trial enrolled 2548 patients with an LVEF  40%.33 
Not only were they all being treated with an ACE inhibitor but 
the majority of them (55%) were also receiving a beta-blocker 
and a signiﬁ  cant number (17%) were receiving spironolactone. 
These patients were therefore already well-treated for their 
chronic HF. During the 41-month follow-up period, the group 
receiving candesartan presented fewer cases of cardiovascular 
death and hospital admissions for chronic HF (primary out-
come) than the placebo group (15% reduction, p = 0.010). 
Moreover, each of the components of this primary outcome 
was reduced by candesartan. We can therefore conclude that 
the candesartan plus ACE inhibitor combination is beneﬁ  cial 
in the treatment of chronic HF with reduced LVEF.
A more recent study also using candesartan but on a 
smaller scale than CHARM-Added was carried out on 
patients with chronic and stable HF with an LVEF  40%.34 
It was carried out on 80 subjects who had had at least 
3 months of optimal, stable ACE inhibitor and beta-blocker 
treatment. In this study, too, the results concerning the ACE 
inhibitor plus candesartan combination are encouraging, as 
the NT-proBNP was 20% lower after 6 months with the 
combined treatment whereas it increased by 12% during the 
same period with ACE inhibitor alone. There is therefore a 
real advantage to carrying out a triple neurohumoral blockade 
in chronic HF patients with low LVEF. This blockade has a 
greater effect on LV remodeling and LVEF.
The CHARM-Alternative trial
A signiﬁ  cant number of patients are ACE inhibitor-intolerant. 
Given the fact that blocking RAAS is vital in chronic HF 
patients, considering alternative treatment with ARBs 
was therefore justifiable. To study this, the CHARM-
Alternative trial was carried out among 2028 ACE inhibitor-
intolerant patients (presenting a cough, hypotension, or 
renal dysfunction) with an LVEF  40%.35 At the end of 
the 34-month follow-up period, this study demonstrated 
that there were fewer cases of cardiovascular deaths and 
hospital admissions for chronic HF in the active treatment 
group than in the placebo group (30% reduction after 
adjustment, p  0.0001), moreover with good ARB tolerance. 
CHARM programme 
(Candesartan vs placebo in chronic HF, N = 7599) 
LVEF ≤ 40%   
CHARM-Added 
(N = 2548; FU = 41 months)  (N = 2028; FU = 34 months)  (N = 3023; FU = 37 months) 
–15% (p = 0.010)   
CV death or hospital admission for chronic HF 
–30% (p < 0.0001) 
LVEF > 40% 
CHARM-Preserved  CHARM-Alternative 
NS
Figure 1 Diagram of the CHARM programme and its main results.
Abbreviations: CV, cardiovascular; FU, follow-up; HF, heart failure; LVEF, left ventricular ejection fraction; NS, non-signiﬁ  cant.Vascular Health and Risk Management 2009:5 261
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The CHARM-Alternative trial therefore demonstrated that 
candesartan can be an effective and safe alternative to ACE 
inhibitors if these are not tolerated by a chronic HF patient.
The effect of candesartan in patients with chronic HF 
and LV systolic dysfunction has been studied in a CHARM 
programme patient sub-group (CHARM-Added or CHARM-
Alternative) which had LVEF  40% (N = 4576).36 After 
a median follow-up period of 40 months, a 12% decrease 
in all-cause mortality (p = 0.018), a 16% decrease in 
cardiovascular mortality (p = 0.005) and a 24% decrease in 
HF hospitalizations (p  0.001) was observed in patients 
who received candesartan. In this study, the positive effects 
of candesartan treatment appeared early on, after as little as 
1 year of treatment, regardless of other treatments taken at the 
same time (ACE inhibitors in 56% of patients, beta-blockers 
in 55%, aldosterone antagonists in 20%).
HF with preserved LV systolic function
The CHARM-Preserved trial
The management strategy to be taken for chronic HF with 
preserved LVEF is not as clearly established as in cases of 
LV systolic dysfunction. It was therefore important to carry 
out a study in order to try to answer the following question: 
is an ARB a useful drug in the treatment of chronic HF with 
preserved LVEF? With this in mind, the CHARM-Preserved 
trial was carried out among 3023 patients with chronic HF, 
with NYHA functional class II-IV and LVEF  40%.26 
At the end of 37 months of follow-up, the administration 
of candesartan in conjunction with the standard therapy 
(beta-blockers for 56% and ACE inhibitors for 20%) had a 
positive impact (16% reduction, p = 0.047) versus placebo 
upon hospitalizations for HF, but its effect on cardiovascular 
deaths was insigniﬁ  cant. In comparison to those obtained in 
the I-Preserve study,27 these results are positive. This could 
be partly explained by the difference in LVEF (mean LVEF 
54% versus 59% in the CHARM-Preserved and I-Preserve 
studies respectively) and BNP levels in the two studies. 
The CHARM-Preserved trial, however, does not enable us 
to conclude that adding an ARB provides any signiﬁ  cant 
improvement to the cardiovascular morbidity and mortality 
associated with chronic HF with preserved LVEF. In this 
speciﬁ  c situation, the 2008 ESC guidelines recommend an 
adequate treatment of hypertension and myocardial ischemia 
along ventricular rate control in patients with AF.6
Candesartan and myocardial infarction
Several studies have shown that ACE inhibitors reduce the 
risk of MI in patients with or without HF.22,23,24,37 However, it 
was not proven, until the results of the CHARM study came 
out, that a similar effect was recognized for ARBs in HF 
patients. During the 38-month follow-up period, the primary 
outcome of cardiovascular death and non-fatal MI was 
signiﬁ  cantly reduced with candesartan (–13%, p = 0.004).38 It 
is important to point out that 53% (N = 4004) of the patients 
included had already experienced an MI and that 41% of 
them received an ACE inhibitor at baseline. The MI rate 
was similar in the group receiving the ACE inhibitor plus 
candesartan combination and the candesartan only group. In 
the same study, candesartan enabled the risk of non-fatal MI 
to be signiﬁ  cantly reduced (–23%, p = 0.03). Candesartan 
therefore seems to have a beneﬁ  cial effect, independent of 
ACE inhibition, on the incidence of MI in HF patients.
Candesartan and atrial ﬁ  brillation
AF is a common condition in chronic HF patients. This 
arrhythmia can be both a cause and a consequence of 
cardiomyopathy, and can trigger systemic emboli. It is 
therefore important to ensure that it occur as late as possible 
or preferably not at all in chronic HF patients. Some 
experimental and clinical studies have shown that certain 
RAAS blockers could prevent AF from occurring. In the 
Val-HeFT study, taking valsartan decreased the incidence 
of AF in patients with reduced LVEF.39 The CHARM pro-
gramme studied the effect of candesartan on the incidence 
of AF in a large cohort of patients (41% receiving an ACE 
inhibitor at baseline) with symptomatic chronic HF and 
decreased or preserved LVEF.40 Among the 6,379 patients 
(84%) without AF on their baseline electrocardiogram, 
392 (6%) developed AF during follow-up. Interestingly, there 
were fewer cases of AF with candesartan than with placebo 
(–20%, p = 0.039). Candesartan therefore seems potentially 
beneﬁ  cial in the prevention of AF during chronic HF.
The protective role of candesartan 
in the treatment of diabetes
Diabetes is a signiﬁ  cant cardiovascular risk factor which 
causes a high number of MIs. Similarly, it is a signiﬁ  cant 
cause of chronic or acute HF. Moreover, diabetes causes 
myocardial lesions through various mechanisms, for example 
by leading to structural anomalies in extracellular matrix 
protein and the development of interstitial ﬁ  brosis.41 It is 
therefore important to treat this disease, whether type 1 or 
type 2 diabetes, both for primary and secondary prevention 
of coronary and/or myocardial events.
Another approach is the prevention of the onset of 
diabetes, by making dietary and lifestyle changes or by Vascular Health and Risk Management 2009:5 262
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taking certain drugs. Among the latter, RAAS blockers are 
predominantly used.42,43,44 The effect of candesartan on the 
incidence of new diabetes cases was studied in the CHARM 
programme among 5436 non-diabetic HF patients out of 
the 7601 enrolled, whether they had a decreased LVEF or 
not.45 In this study, candesartan decreased the incidence of 
new diabetes cases by 22% compared to placebo (6.0 versus 
7.4%, p = 0.02). This beneﬁ  t appeared to be smaller in those 
receiving a concomitant ACE inhibitor compared with those 
who were not. This positive effect can in part be explained 
by the fact that angiotensin II is involved in the development 
of adipose tissue and that it modiﬁ  es the response of certain 
cytokines to insulin.
In a study carried out among HF patients already being 
treated with an ACE inhibitor and a beta-blocker, adding 
candesartan decreased blood glucose to a greater extent 
in subjects with poorer glycemic control.34 In this study, 
further analyzes of insulin and fasting insulin resistance 
index suggest that candesartan is likely to improve glycemic 
control by increasing insulin release and also by improving 
insulin sensitivity.
Candesartan and inﬂ  ammation
Patients with decompensated or compensated HF exhibit 
systemic inﬂ  ammation, believed to be caused by the increase 
in hsCRP. In the Val-HeFT study, no signiﬁ  cant changes in 
CRP were observed in patients already being treated with an 
ACE inhibitor with or without a beta-blocker.46 Conversely, 
White et al demonstrated that adding candesartan to an 
ACE inhibitor plus beta-blocker combination signiﬁ  cantly 
decreased (–20% versus +5% on placebo) plasma levels of 
hsCRP after six months of treatment.34
Quality of life and tolerance 
of candesartan
Importantly, in terms of the quality of life of HF patients, 
the addition of candesartan to conventional treatment 
signiﬁ  cantly improves NYHA class compared to placebo.47 
However, this positive effect was not detected in the CHARM 
preserved trial, which is probably a reﬂ  ection of the low 
proportion of patients in NYHA class III/IV (39%) in this 
trial compared to the two low LVEF trials (53% in CHARM 
alternative and 76% in CHARM added).
In the Young et al study, adding candesartan to standard 
therapy (including ACE inhibitors) was shown to cause more 
side effects (p  0.001) than placebo, particularly increased 
plasma creatinine levels (7.1% versus 3.5%), hypotension 
(4.2% versus 2.1%) and hyperkalemia (2.8% versus 0.5%).36 
During the CHARM trial, the authors observed an increased 
risk of hyperkalemia (ie, kalemia  5.0 mmol/L), with 5.2% 
prevalence in the candesartan group versus 1.8% in the 
placebo group.48 The risk of hyperkalemia increased with 
the following factors: age  75 years, male gender, diabetes, 
creatinine  2.0 mg/dL, K+  5.0 mmol/L at baseline, 
and background use of ACE inhibitors or spironolactone. 
However, in the CHARM-Alternative trial, study-drug 
discontinuation rates were similar in the candesartan (30%) 
and placebo (29%) groups.35 Moreover, the relative risk 
of discontinuation of candesartan (compared to placebo) 
because of hypotension, increased serum creatinine or 
hyperkalemia was not increased in patients taking the triple 
association of an ACE inhibitor plus spironolactone plus 
candesartan.49
A recent substudy of the CHARM programme was 
performed to assess the role of age on the efﬁ  cacy and safety 
of candesartan.50 In this study, the risk of cardiovascular death 
or hospitalization for HF increased from 24% in the lowest 
age group to 46% in the highest (and mortality from 13% 
to 42%). Interestingly, the absolute beneﬁ  t of candesartan 
treatment was greater the older the patient, without an 
increase in adverse effects in the oldest patients. It is however 
essential to keep a close watch on serum potassium and 
creatinine levels when monitoring patients on candesartan, 
particularly when combined with an ACE inhibitor and/or 
spironolactone.
Conclusions
As recommended by the 2008 ESC guidelines on HF: “Unless 
contraindicated or not tolerated, an ARB is recommended 
in patients with HF and an LVEF  40% who remain 
symptomatic despite optimal treatment with an ACE inhibitor 
and beta-blocker, unless they are also taking an aldosterone 
antagonist.”6 The ARB candesartan signiﬁ  cantly reduces 
cardiovascular death, hospital admission for decompensated 
HF, and all-cause mortality in chronic HF patients with 
LVEF  40%, when added to standard therapies including 
ACE inhibitors, beta-blockers, and an aldosterone antagonist, 
or a combination of these. On the other hand, in patients 
with HF and preserved LVEF, adding candesartan does not 
provide any signiﬁ  cant improvement to the cardiovascular 
morbi-mortality. In cases of ACE inhibitor-intolerance, 
candesartan is a safe and effective alternative. Candesartan 
also has a protective effect against incidence of MI, AF 
and diabetes (Table 1). Although candesartan tolerance is 
generally good, monitoring of blood pressure, and serum 
creatinine and potassium is warranted. This approach allows Vascular Health and Risk Management 2009:5 263
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the clinician to improve the prognosis of patients with chronic 
HF and LV systolic dysfunction by using candesartan.
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